Abstract 3666
Background
Immune-related adverse events (IRAEs) represent a clinical challenge, potentially limiting the clinical benefits of immunotherapy. Data suggests nivolumab and pembrolizumab IRAEs rates are similar but no comparisons across tumor types exist. Therefore, we studied IRAEs in patients (pts) with metastatic melanoma and non-small cell lung cancer (NSCLC) treated with anti-PD1 therapy.
Methods
All pts with metastatic melanoma and NSCLC seen at the Mayo Clinic Rochester and Florida from 2015 to 2018 were reviewed. Patients that received prior immunotherapies or thoracic radiation were excluded. Chi-square test was used to estimate differences in categorical data.
Results
Out of 510 pts, 266 (52%) had melanoma and 244 (48%) NSCLC. Baseline characteristics were similar across groups, except for sex (NSCLC: 51% women; melanoma: 40% women). 80% of the pts with NSCLC received chemotherapy prior to immunotherapy compared to 14% of the pts with melanoma. 75% (200) of melanoma pts received pembrolizumab and 66% (161) of NSCLC pts received nivolumab. Higher rates of IRAEs were observed in the melanoma pts (55% vs. 41%, <0.001) (Table). No difference in grade ≥3 IRAEs was observed. Melanoma pts were more likely to develop diarrhea/colitis and endocrinopathies compared to the NSCLC pts (19% vs. 7%, p < 0.008; 33% vs. 18%, p < 0.01, respectively). Contrarily, pts with NSCLC had higher rates of pneumonitis (14% vs. 6%, p < 0.007). Most pts resumed the anti-PD1 agent after developing IRAEs (60% and 57%, respectively). In 31% of the pts experiencing IRAEs the anti-PD1 agent was permanently discontinue due to toxicity.Table: 1218P
| Melanoma % (n) | NSCLC % (n) | p value | |
|---|---|---|---|
| IRAEs | 55 (146) | 41 (99) | <0.001 |
| Grade ≥2 IRAEs | 76 (110) | 75 (76) | 0.98 |
| Grade ≥3 IRAEs | 34 (49) | 36 (36) | 0.68 |
| Prescribed systemic steroids | 66 (97) | 60 (59) | 0.26 |
| Required intravenous steroids | 25 (37) | 27 (27) | 0.75 |
| IRAEs: Subtype (all grades) | |||
| Diarrhea/Colitis | 19 (28) | 7 (7) | 0.008 |
| Dermatologic Toxicities | 19 (28) | 22 (22) | 0.62 |
| Endocrinopathies | 33 (48) | 18 (18) | 0.01 |
| Pneumonitis | 6 (8) | 14 (14) | 0.007 |
| Transaminitis | 14 (21) | 9 (9) | 0.24 |
| Immunotherapy was restarted | 60 (88) | 57 (56) | 0.60 |
| Immunotherapy DC due to toxicity | 31 (45) | 31 (31) | 0.99 |
Conclusions
Patients with metastatic melanoma were more likely to develop IRAEs with anti-PD1 therapy. We observed differences in the IRAEs developed across groups. These associations could be attributed to intrinsic tumor characteristics or differences between anti-PD1 agents. Larger studies are needed to enhance our understanding of these differences.
Clinical trial identification
Legal entity responsible for the study
N. Duma.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract